Bariatric Surgery-Induced Cardiac and Lipidomic Changes in Obesity-Related Heart Failure with Preserved Ejection

Deana Mikhalkova1, Sujata R Holman1, Hui Jiang2

  • 1Cardiovascular Division, Department of Medicine, School of Medicine, Washington University, St Louis, Missouri, USA.

Insights

Gastric bypass surgery improved heart failure symptoms and cardiac function in obese women. Weight loss reduced cardiac mass and liver fat, but cardiac fat and lipid changes were not directly linked to functional improvements.

Area of Science:

  • Cardiology
  • Metabolic Surgery
  • Obesity Medicine

Background:

  • Obesity is a significant risk factor for heart failure with preserved ejection fraction (HFpEF).
  • Myocardial lipid deposition and altered plasma lipidome are implicated in HFpEF pathogenesis.
  • The impact of bariatric surgery on cardiac function and lipid metabolism in HFpEF remains incompletely understood.

Purpose of the Study:

  • To investigate the effects of gastric bypass surgery on myocardial lipid deposition, cardiac function, and plasma lipidome in women with obesity and HFpEF.

Main Methods:

  • A primary cohort of 12 women with HFpEF and obesity underwent echocardiography and magnetic resonance spectroscopy pre- and post-surgery (3 and 6 months).
  • Plasma lipidomic analysis was performed pre-surgery and 3 months post-surgery.
  • A validation cohort of 22 patients confirmed key findings.

Main Results:

  • Gastric bypass surgery led to significant weight loss, reduced Minnesota Living with Heart Failure scores, decreased cardiac mass, and lowered liver fat.
  • Echocardiography showed improved diastolic function (increased e'), but cardiac fat remained unchanged.
  • Weight loss was associated with decreased plasma ceramide and sphingolipid species, yet these changes did not correlate with improvements in cardiac function.

Conclusions:

  • Gastric bypass surgery ameliorates symptoms and improves cardiac remodeling and relaxation in women with obesity-related HFpEF.
  • While surgery impacts the plasma sphingolipidome, improvements in cardiac function are not directly associated with these lipidomic changes or altered myocardial triglyceride content.
  • Cardiac fat deposition and specific lipidomic alterations may not be the primary drivers of obesity-related HFpEF, suggesting alternative therapeutic targets.
Abstract

Related Concept Videos

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
301
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
4.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.0K
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
483
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
197
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
549